Screener
Krystal Biotech, Inc. KRYS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Krystal Biotech, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
FAQ
- What is Krystal Biotech, Inc.'s EBITDA margin?
- Krystal Biotech, Inc. (KRYS) reported EBITDA margin of 44.2% in Q1 2026.
- How has Krystal Biotech, Inc.'s EBITDA margin changed year-over-year?
- Krystal Biotech, Inc.'s EBITDA margin increased by 28.7% year-over-year, from 34.4% to 44.2%.
- What is the long-term trend for Krystal Biotech, Inc.'s EBITDA margin?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s EBITDA margin has grown at a -55.3% compound annual growth rate (CAGR), from -214.5% to 42.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Krystal Biotech, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude